Latent TB is not immediately dangerous. You won’t feel sick, you can’t spread it to anyone, and most people with latent TB never develop active disease. But it does carry a real, lifelong risk: about 10% of people with normal immune systems will eventually see their latent infection become active TB, which is serious and contagious. That risk makes latent TB worth understanding and, in many cases, worth treating.
What Happens Inside Your Body
When you breathe in TB bacteria, most of them are destroyed by your immune system right away. A small number survive and can spread through your bloodstream to the lungs, kidneys, brain, bones, or lymph nodes. Within two to eight weeks, your immune cells surround these remaining bacteria and form tiny walled-off structures called granulomas. Think of them as microscopic prisons: the bacteria are alive inside, but they’re inactive and contained.
This standoff between your immune system and the bacteria is latent TB infection. You have no symptoms, a normal chest X-ray, and zero ability to pass TB to others. The bacteria are simply sitting there, held in check.
The Real Risk: Reactivation
The danger of latent TB isn’t what it’s doing now. It’s what it could do later. About 5% of people with latent TB develop active disease within the first two years of infection. Over a full lifetime, that number reaches roughly 10%. When TB reactivates, it causes the serious, symptomatic form of the disease: coughing, weight loss, fever, and the ability to spread bacteria to others through the air.
Those numbers apply to people with otherwise healthy immune systems. If something weakens your immune defenses, the risk climbs significantly. The CDC identifies several conditions and situations that make reactivation much more likely:
- HIV infection, which directly attacks the immune cells that keep TB contained
- Immunosuppressive medications, including corticosteroids and treatments for rheumatoid arthritis or Crohn’s disease
- Organ transplants, which require drugs that deliberately lower immune function
- Diabetes
- Severe kidney disease
- Injection drug use
- Low body weight
- Very young age, since children under five have immature immune systems
For people in these groups, treating latent TB is considered especially important because their odds of reactivation are far higher than the baseline 10%.
How Latent TB Is Detected
Latent TB produces no symptoms, so it’s only found through testing. There are two options: a skin test and a blood test. Both measure your immune system’s response to TB proteins rather than detecting the bacteria directly.
The skin test involves injecting a small amount of protein under the skin of your forearm and checking for a raised bump 48 to 72 hours later. It’s been used for decades and is still the preferred method for children under five. The blood test, called an IGRA, requires a single blood draw with no return visit. It has an important advantage for people who received the BCG vaccine (a TB vaccine given routinely in many countries): it won’t produce a false positive the way the skin test often does in vaccinated individuals.
Neither test is perfect. Both can miss an infection if it occurred within the past eight weeks, because the immune response takes time to develop. If you’ve been recently exposed to someone with active TB, a negative result should be repeated 8 to 10 weeks after the last contact. People with advanced HIV or severe immune suppression can also get false negatives because their immune systems are too weak to mount the reaction the test relies on.
A positive result on either test means you likely have latent TB, but additional evaluation, typically a chest X-ray, is needed to confirm the infection hasn’t already become active.
Treatment Options and What to Expect
Treating latent TB eliminates the risk of reactivation. The CDC now recommends shorter treatment courses over the older regimens that lasted six to nine months. The preferred options take three to four months:
- 3-month weekly regimen: two medications taken once a week for 12 weeks
- 4-month daily regimen: a single medication taken daily for four months
- 3-month daily regimen: two medications taken daily for three months
Older regimens using a single daily medication for six or nine months are still available but are considered alternatives. The shorter courses have comparable effectiveness and, because they’re easier to complete, tend to produce better real-world results.
Treatment is straightforward but requires commitment. Missing doses reduces effectiveness, and your provider will monitor you for side effects, particularly liver-related issues. If you complete the full course, the bacteria are cleared and the risk of future reactivation drops dramatically.
How Common Latent TB Is Worldwide
Roughly one-quarter of the world’s population, about 1.7 billion people, carries latent TB. That figure was revised downward from earlier estimates of one-third, based on improved global surveillance. The prevalence varies enormously by region: it’s far higher in parts of Southeast Asia and sub-Saharan Africa than in North America or Western Europe.
The vast majority of these 1.7 billion people will never develop active TB. But because the global pool of latent infections is so large, even a small reactivation percentage translates into millions of new active TB cases each year. This is why public health programs focus heavily on identifying and treating latent TB in people at elevated risk, particularly those with weakened immune systems or recent close contact with someone who has active disease.
The Bottom Line on Risk
Latent TB is not an emergency. It won’t make you sick today, and it poses zero risk to the people around you. But it’s also not something to ignore. A 10% lifetime chance of developing a serious, transmissible lung disease is a meaningful risk, especially if you have any condition that compromises your immune system. Treatment is short, effective, and eliminates that risk almost entirely.